Applicant, as named in the Orange Book

Novartis Pharms Corp

Next listed expiry: Jadenu on 21 Nov 2034. 2 products with live protection, 0 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Jadenu · 3 strengths deferasirox	deferasirox	206910	21 Nov 2034	patent
Entresto · 3 strengths sacubitril; valsartan	sacubitril; valsartan	207620	9 May 2036	patent, carve-out possible